Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PPV23 Revaccination in Elderly
NCT04700618Phase 4Completed
- Sponsor
- China National Biotec Group
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection (2 arms), sponsored by China National Biotec Group. Primary endpoint: Antibody double growth rate. Started Mar 2021; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04700618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700618.